SARATOGA, Calif. & BARCELONA, Spain--(EON: Enhanced Online News)--The Myelin Repair Foundation (MRF) and Bionure, Inc. today entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis (MS). The Foundation’s unique Accelerated Research Collaboration™ (ARC™) model facilitates collaboration between the top MS leaders worldwide to advance promising compounds into the clinic. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company’s proprietary MS therapeutic compound, BN201.
“By leveraging our non-profit status to collaborate with global innovative MS companies such as Bionure, our strategy is to investigate and advance many promising MS compounds towards commercialization.”
Through this unique partnership, Bionure, Inc. will collaborate with MRF researchers at the Myelin Repair Foundation’s Translational Medicine Center, an industry-standard laboratory facility dedicated to the evaluation of promising myelin repair candidates for MS. At the laboratory, MRF scientists with extensive biopharma experience moving therapeutic compounds into the clinic will assess Bionure’s BN201 for its neuroprotective properties to enhance remyelination. BN201 is a potential MS treatment for acute optic neuritis and severe MS relapses.
“We are excited to partner with the Myelin Repair Foundation to advance our compound closer to the clinic,” said CEO Albert G. Zamora at Bionure, Inc. “With the top scientific expertise and innovative myelin repair research tools and assays at the MRF, this partnership will accelerate our progress towards addressing the unmet needs of MS patients.”
“In our world-wide search for innovative MS companies, Bionure is an ideal partner for us, given their unique approach to treat MS,” said Chief Research Officer Dr. Jay Tung, Ph.D. at the Myelin Repair Foundation. “By leveraging our non-profit status to collaborate with global innovative MS companies such as Bionure, our strategy is to investigate and advance many promising MS compounds towards commercialization.”
The Myelin Repair Foundation’s rigorous, industry-leading Translational Medicine Platform ensures comprehensive scientific validation of potential therapeutics for MS clinical trials. Dr. Larry Steinman from Stanford University is an advisory board member at Bionure, Inc.
About the Myelin Repair Foundation
The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the process of medical research, drug development and the delivery of new patient treatments.
About Bionure, Inc.
Bionure, Inc. (www.bionure.com) is a Silicon Valley and Barcelona based early stage drug development company focused on developing neuroprotective therapies for the treatment of neurodegenerative diseases. Bionure will enter into the clinic for Acute Optic Neuritis/Neuromyelitis Optica in 2014 (Orphan drug designation).